Device Trial Radar · NCT01925794
COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT
Last checked: Nov 20, 2026Latest source record: Dec 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
296
Actual
Start
Aug 21, 2013
Primary completion
Nov 2015
Study completion Mar 2, 2020
Sponsor
- Lead sponsor
- CeloNova BioSciences, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 20, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and Outside United States (OUS). This study will enroll patients with symptomatic ischemic heart disease due to a single de novo lesion contained within a native coronary artery with reference vessel diameter between 2.5 mm and 4.0 mm and lesion length ≤ 24 mm that is amenable to percutaneous coronary intervention (PCI) and stent deployment. All patients will be followed at 30 days, 6 months, 9 months, 1 year and annually for 5 years post index stenting procedure.
Conditions
- Coronary Artery Disease
Interventions
COBRA PzFDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Target Vessel Failure (TVF)Time frame: 270 days
Locations
35 sites in 7 countries. Site status is shown where the registry gives one.
Bakersfield Memorial Hospital
Bakersfield, California
34 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.